First Interim Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hui Liang, Yiying Cheng, Haiyang Yang, Liting Zhang, Liping Zou, Y. Guo, Junming Cao, Huaipeng Huang, Zhe Wang, Sha Huang, Zhiyi Liang, Jiyuan Lyu, Yiqian Fang, Lifeng Cohen, Kishu Zhou

Department of Hematology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China; 2Department of Hematology, Jilin Cancer Hospital, Changchun, China; 3Department of Hematology, Southwest Hospital, Third Military Medical University, Chongqing, China; 4Department of Hematology, West China Hospital, Sichuan University, Chengdu, China; 5Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; 6Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; 7Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; 8United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 9United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 10United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 11United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 12United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 13United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 14United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 15United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 16United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 17United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 18United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 19United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 20United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 21United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 22United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 23United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 24United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 25United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 26United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 27United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 28United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 29United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 30United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 31United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 32United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 33United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China; 34United Therapeutics Corporation, Ad经营管理有限公司, Beijing, China;

BACKGROUND

Objective: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have limited treatment options and a high mortality rate. Therefore, we conducted a phase 1 study to evaluate the safety and efficacy of zanubrutinib (Zan) plus lenalidomide (L) in patients with relapsed or refractory DLBCL.

Methods: This was a phase 1, dose-escalation study conducted at 13 centers in China. Patients with relapsed or refractory DLBCL, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2, and an International Prognostic Index (IPI) of 1–3 were eligible. Zan was administered twice daily (BID) at 160 mg or 240 mg and L at 15 mg once daily (QD) at 10 mg or 15 mg QD. The recommended part 2 dose (RP2D) was determined based on a phase 1 dose-finding study.

RESULTS

Patients with ≥1 TEAE4

Table 1: Patient Demographics and Baseline Disease Characteristics

Table 2: TEAEs

CONCLUSIONS

The zanubrutinib 160 mg twice daily plus lenalidomide 25 mg once daily combination demonstrated an acceptable safety profile and promising efficacy in patients with R/R DLBCL. Further evaluation of the combination in a larger sample is planned in future analyses.

REFERENCES


DISCLAIMERS

The information provided in this document is for informational purposes only. It is not intended to be a substitute for professional medical advice. Always consult a qualified medical professional for guidance in your specific situation.